The report also finds that Seroquel has gained ground among both psychiatrists and PCPs as a first-line monotherapy and maintenance treatment. Seroquel captures 14.5% patient share first line, up 13.1% from just two years ago. Seroquel will continue to acquire patient share in all lines of therapy, largely owing to its first-in-class status among the antipsychotics to treat both mania and depression. Janssen's Risperdal and Eli Lilly's Zyprexa suffered the greatest losses, losing a combined 11.9% patient share first line over the same time period.
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.
For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:
-- Summary of U.S. medical practice based on interviews with leading
experts in the field
-- Qualitative diagnosis/referral/treatment algorithm for the United
-- Drug usage by lines of therapy (1st, 2nd, 3rd line)
-- Discussion of key freeform combinations by lines of therapy
-- Product share (class and specific compound level) within each line of
therapy (1st, 2nd, 3rd line)
-- Progression of therapy from key 1st line products
-- Pathway to key therapies from previous therapies
-- Qualitative analysis of 2-year forecast incorporating upcoming
launches, changes in reimbursement, etc.
About Decision Resources
Decision Resources, Inc., (http://www.DecisionResources.com) is a world
leader in healthcare market research publications, advisory services, and
|SOURCE Decision Resources|
Copyright©2007 PR Newswire.
All rights reserved